fluorouracil has been researched along with Esophagitis in 25 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
Esophagitis: INFLAMMATION, acute or chronic, of the ESOPHAGUS caused by BACTERIA, chemicals, or TRAUMA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Patients with previously untreated thoracic AEC who had T4 tumors or M1 lymph node metastasis (M1 LYM), or both, received intravenous infusions of docetaxel (35 mg/m(2)) and cisplatin (40 mg/m(2)) on day 1 and a continuous intravenous infusion of 5-fluorouracil (400 mg/m(2)/day) on days 1 to 5, every 2 weeks, plus concurrent radiation." | 5.19 | Definitive chemoradiation therapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) in advanced esophageal cancer: a phase 2 trial (KDOG 0501-P2). ( Azuma, M; Hayakawa, K; Higuchi, K; Ishido, K; Ishiyama, H; Katada, C; Katada, N; Koizumi, W; Komori, S; Sasaki, T; Tanabe, S, 2014) |
| "A 61-year-old man, with a tuberous sclerosis, experienced severe acute reactions during a concomitant chemoradiotherapy regimen after 22Gy and one cycle of 5-fluorouracil-cisplatinum." | 3.79 | [Hypersensitivity to radiation therapy in a patient with tuberous sclerosis: biological considerations about a clinical case]. ( Baruch-Hennequin, V; Duchemain, B; Duchemann, B; Hennequin, C; Quero, L; Rivera, S; Wong, S, 2013) |
| "Patient survival in esophageal cancer (EC) remains poor." | 2.80 | A Phase 1/2 Study of Definitive Chemoradiation Therapy Using Docetaxel, Nedaplatin, and 5-Fluorouracil (DNF-R) for Esophageal Cancer. ( Hayashi, T; Hirakawa, M; Hori, M; Kato, J; Kobune, M; Miyanishi, K; Nakata, K; Ohnuma, H; Okagawa, Y; Osuga, T; Sagawa, T; Sakata, K; Sato, T; Sato, Y; Someya, M; Takayama, T; Takimoto, R, 2015) |
| "Patients with stage II and III esophageal cancer were enrolled." | 2.77 | Phase I evaluation of TNFerade biologic plus chemoradiotherapy before esophagectomy for locally advanced resectable esophageal cancer. ( Chak, A; Chang, KJ; Hanna, N; Pinto, H; Reid, T; Senzer, N; Soetikno, R; Swisher, S, 2012) |
| "To evaluate the efficacy of late accelerated hyperfractionated conformal radiotherapy (LACF) combined with capecitabine on esophageal carcinoma." | 2.76 | [Efficacy of late accelerated hyperfractionated conformal radiotherapy combined with capecitabine for esophageal carcinoma]. ( Feng, XZ; Han, JQ; Sheng, W, 2011) |
| "Forty-four patients with esophageal squamous cell carcinoma (ESCC) were randomized into two groups." | 2.73 | [Phase II clinical trial of concurrent chemoradiotherapy (cisplatin plus 5-fluorouracil) for esophageal cancer]. ( Chen, K; Gao, XS; Lin, Q; Qiao, XY; Wang, YD; Zhou, ZG, 2008) |
| " Thus, the recommended dosing schedule is level 2." | 2.72 | A phase I/II study of nedaplatin and 5-fluorouracil with concurrent radiotherapy in patients with esophageal cancer. ( Abe, S; Araki, H; Hareyama, M; Iyama, S; Kato, J; Miyanishi, K; Murase, K; Nagakura, H; Niitsu, Y; Okamoto, T; Sagawa, T; Sato, T; Sato, Y; Takayama, T; Takimoto, R, 2006) |
| "Forty patients with esophageal cancer were treated in a phase I and II trial of induction chemotherapy (cisplatin, 5-fluorouracil, and paclitaxel) at three dosage levels (75, 125, and 100 mg/m2) and concurrent hyperfractionated radiotherapy (45 Gy to the mediastinum, 58." | 2.68 | Induction therapy for esophageal cancer with paclitaxel and hyperfractionated radiotherapy: a phase I and II study. ( Carey, RW; Choi, NC; Grillo, HC; Grossbard, ML; Lynch, TJ; Mathisen, DJ; Moncure, AC; Wain, JC; Wright, CD, 1997) |
| "5-Fluorouracil was infused 24 hours per day throughout the period of radiation at a dose of 300 mg/m2/day for a median of 42 days (range, 28-56 days)." | 2.66 | Concomitant 5-fluorouracil infusion and high-dose radiation for stage III non-small cell lung cancer. ( Chaffey, J; Lokich, J; Neptune, W, 1989) |
| "Pursuant to this, the North Central Cancer Treatment Group has developed a series of clinical trials designed to study antidotes for these pathologic processes." | 2.39 | Alleviation of cytotoxic therapy-induced normal tissue damage. ( Foote, RL; Loprinzi, CL; Michalak, J, 1995) |
| "Lobaplatin plus 5-Fu combined with concurrent radiotherapy is safe and effective in treating patients with middle-advanced stage esophageal cancer." | 1.42 | Clinical Study on Lobaplatin Combined with 5-Fu and Concurrent Radiotherapy in Treating Patients with Inoperable Esophageal Cancer. ( Huang, JZ; Jia, XJ, 2015) |
| " CM-Na was given 1 h before radiotherapy at Monday, Wednesday, and Friday every week, combined with 2 circles of continuous 5-day chemotherapy of 500 mg x (m(2) x d)(-1) of 5-fluoruracil (5-FU) and 20 mg x (m(2) x d)(-1) of cisplatin (DDP) at the first and the fifth week." | 1.33 | [Phase I study of CM-Na combined with concurrent radiochemotherapy for advanced esophageal carcinoma]. ( Cai, L; Chen, EC; Cui, NJ; Gu, MF; Hu, YH; Huang, Y; Li, QQ; Lin, HX; Liu, H; Liu, MZ; Rong, TH; Wang, HY, 2005) |
| "HDRBT is safe and beneficial for local control in the radical treatment of patients with esophageal cancer." | 1.33 | The safety and usefulness of high-dose-rate endoluminal brachytherapy as a boost in the treatment of patients with esophageal cancer with external beam radiation with or without chemotherapy. ( Burtin, P; Corns, R; David, M; Devic, S; Evans, M; Faria, S; Mayrand, S; Parent, J; Szego, P; Vuong, T, 2005) |
| " The 5-fluoro-uracil was given intravenously at a relatively nontoxic dosage level." | 1.24 | The potentiation of radiation effects with 5-fluoro-uracil. ( FOYE, LV; HALL, B; ROTH, M; WILLETT, FM, 1960) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (16.00) | 18.7374 |
| 1990's | 3 (12.00) | 18.2507 |
| 2000's | 7 (28.00) | 29.6817 |
| 2010's | 11 (44.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kato, K | 1 |
| Nakajima, TE | 1 |
| Ito, Y | 1 |
| Katada, C | 2 |
| Ishiyama, H | 2 |
| Tokunaga, SY | 1 |
| Tanaka, M | 1 |
| Hironaka, S | 1 |
| Hashimoto, T | 1 |
| Ura, T | 1 |
| Kodaira, T | 1 |
| Yoshimura, K | 1 |
| Babacan, T | 1 |
| Turkbeyler, IH | 1 |
| Dag, MS | 1 |
| Dilli, I | 1 |
| Balakan, O | 1 |
| Altundag, K | 1 |
| Higuchi, K | 1 |
| Komori, S | 1 |
| Tanabe, S | 1 |
| Azuma, M | 1 |
| Sasaki, T | 1 |
| Ishido, K | 1 |
| Katada, N | 1 |
| Hayakawa, K | 1 |
| Koizumi, W | 1 |
| Gaduputi, V | 1 |
| Tariq, H | 1 |
| Ihimoyan, A | 1 |
| Ohnuma, H | 1 |
| Sato, Y | 2 |
| Hirakawa, M | 1 |
| Okagawa, Y | 1 |
| Osuga, T | 1 |
| Hayashi, T | 1 |
| Sato, T | 2 |
| Miyanishi, K | 2 |
| Kobune, M | 1 |
| Takimoto, R | 2 |
| Sagawa, T | 2 |
| Hori, M | 1 |
| Someya, M | 1 |
| Nakata, K | 1 |
| Sakata, K | 1 |
| Takayama, T | 2 |
| Kato, J | 2 |
| Jia, XJ | 1 |
| Huang, JZ | 1 |
| Lin, Q | 1 |
| Gao, XS | 1 |
| Qiao, XY | 1 |
| Chen, K | 1 |
| Wang, YD | 1 |
| Zhou, ZG | 1 |
| Zemanova, M | 1 |
| Petruzelka, L | 1 |
| Pazdro, A | 1 |
| Kralova, D | 1 |
| Smejkal, M | 1 |
| Pazdrova, G | 1 |
| Honova, H | 1 |
| Sheng, W | 1 |
| Feng, XZ | 1 |
| Han, JQ | 1 |
| Chang, KJ | 1 |
| Reid, T | 1 |
| Senzer, N | 1 |
| Swisher, S | 1 |
| Pinto, H | 1 |
| Hanna, N | 1 |
| Chak, A | 1 |
| Soetikno, R | 1 |
| Bi, LW | 1 |
| Zhang, LZ | 1 |
| Zhao, HF | 1 |
| Duchemann, B | 1 |
| Duchemain, B | 1 |
| Wong, S | 1 |
| Baruch-Hennequin, V | 1 |
| Rivera, S | 1 |
| Quero, L | 1 |
| Hennequin, C | 1 |
| Videtic, GM | 1 |
| Campbell, C | 1 |
| Vincent, MD | 1 |
| FOYE, LV | 1 |
| WILLETT, FM | 1 |
| HALL, B | 1 |
| ROTH, M | 1 |
| MOERTEL, CG | 1 |
| REITEMEIER, RJ | 1 |
| HAHN, RG | 1 |
| Patonay, P | 1 |
| Naszály, A | 1 |
| Mayer, A | 1 |
| Ishida, K | 1 |
| Ando, N | 1 |
| Yamamoto, S | 1 |
| Ide, H | 1 |
| Shinoda, M | 1 |
| Cai, L | 1 |
| Liu, MZ | 1 |
| Gu, MF | 1 |
| Liu, H | 1 |
| Chen, EC | 1 |
| Hu, YH | 1 |
| Lin, HX | 1 |
| Wang, HY | 1 |
| Huang, Y | 1 |
| Li, QQ | 1 |
| Cui, NJ | 1 |
| Rong, TH | 1 |
| Vuong, T | 1 |
| Szego, P | 1 |
| David, M | 1 |
| Evans, M | 1 |
| Parent, J | 1 |
| Mayrand, S | 1 |
| Corns, R | 1 |
| Burtin, P | 1 |
| Faria, S | 1 |
| Devic, S | 1 |
| Okamoto, T | 1 |
| Araki, H | 1 |
| Iyama, S | 1 |
| Abe, S | 1 |
| Murase, K | 1 |
| Nagakura, H | 1 |
| Hareyama, M | 1 |
| Niitsu, Y | 1 |
| Smith, FP | 1 |
| Schein, PS | 1 |
| Macdonald, JS | 1 |
| Woolley, PV | 1 |
| Ornitz, R | 1 |
| Rogers, C | 1 |
| Loprinzi, CL | 1 |
| Foote, RL | 1 |
| Michalak, J | 1 |
| Ohtsu, A | 1 |
| Yoshida, S | 1 |
| Boku, N | 1 |
| Fujii, T | 1 |
| Miyata, Y | 1 |
| Hosokawa, K | 1 |
| Koba, I | 1 |
| Shimizu, W | 1 |
| Ogino, T | 1 |
| Wright, CD | 1 |
| Wain, JC | 1 |
| Lynch, TJ | 1 |
| Choi, NC | 1 |
| Grossbard, ML | 1 |
| Carey, RW | 1 |
| Moncure, AC | 1 |
| Grillo, HC | 1 |
| Mathisen, DJ | 1 |
| Lokich, J | 1 |
| Chaffey, J | 1 |
| Neptune, W | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Open-label, Multicenter Trial of the Chemoradiation Versus Standard Esophagectomy for Locally Advanced Resectable Esophageal Squamous Cell Cancer in Chinese Patients[NCT02972372] | 196 participants (Anticipated) | Interventional | 2016-11-30 | Recruiting | |||
| Two-arm Phase III Trial Comparing Radiotherapy With Differentcycles of Cisplatin-5-fluorouracil for Esophageal Cancer[NCT02607540] | Phase 3 | 210 participants (Anticipated) | Interventional | 2014-10-31 | Recruiting | ||
| Three-arm Phase III Trial Comparing Radiotherapy With Different Chemotherapy Regimens for Esophageal Cancer[NCT02025036] | Phase 3 | 249 participants (Actual) | Interventional | 2014-10-31 | Active, not recruiting | ||
| Concurrent Docetaxel Plus Cisplatin or Cisplatin Alone With Intensity-modulated Radiotherapy in High Risk Locregionally Advanced Nasopharyngeal Carcinoma: a Phase 2 Randomized Controlled Trial[NCT02610556] | Phase 2 | 130 participants (Anticipated) | Interventional | 2016-01-31 | Recruiting | ||
| A Single Arm, Phase II Study of TNFerade™ Biologic Gene Therapy + Radiation + 5-FU and Cisplatin in Locally Advanced, Resectable, Esophageal Cancer[NCT00051480] | Phase 2 | 0 participants | Interventional | Completed | |||
| Phase I Study of Chemoradiation Therapy With Epitope Peptide Vaccine Therapy in Treating Patients With Unresectable, Advanced or Recurrent Esophageal Cancer[NCT00632333] | Phase 1 | 9 participants (Anticipated) | Interventional | 2008-02-29 | Recruiting | ||
| A Prospective, Phase Ⅱ Study of S-1 Plus Moderately Hypofractionated Conformal Radiation for Esophageal Squamous Cell Carcinoma[NCT03660449] | Phase 2 | 58 participants (Actual) | Interventional | 2017-10-01 | Completed | ||
| A Prospective, Single-arm Study of Simultaneous Modulated Accelerated Radiotherapy Combined With S-1/DDP for Elderly Esophageal Squamous Cell Carcinoma.[NCT02606916] | Phase 2 | 42 participants (Actual) | Interventional | 2015-07-31 | Completed | ||
| trūFreeze® Spray Cryotherapy Patient Registry[NCT01802203] | 275 participants (Actual) | Observational [Patient Registry] | 2013-04-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for fluorouracil and Esophagitis
| Article | Year |
|---|---|
Alleviation of cytotoxic therapy-induced normal tissue damage.
Topics: Chlorhexidine; Clinical Trials as Topic; Cryotherapy; Dermatitis; Esophagitis; Eye Diseases; Fluorou | 1995 |
12 trials available for fluorouracil and Esophagitis
| Article | Year |
|---|---|
Phase II study of concurrent chemoradiotherapy at the dose of 50.4 Gy with elective nodal irradiation for Stage II-III esophageal carcinoma.
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Che | 2013 |
Phase II study of concurrent chemoradiotherapy at the dose of 50.4 Gy with elective nodal irradiation for Stage II-III esophageal carcinoma.
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Che | 2013 |
Phase II study of concurrent chemoradiotherapy at the dose of 50.4 Gy with elective nodal irradiation for Stage II-III esophageal carcinoma.
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Che | 2013 |
Phase II study of concurrent chemoradiotherapy at the dose of 50.4 Gy with elective nodal irradiation for Stage II-III esophageal carcinoma.
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Che | 2013 |
Phase II study of concurrent chemoradiotherapy at the dose of 50.4 Gy with elective nodal irradiation for Stage II-III esophageal carcinoma.
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Che | 2013 |
Phase II study of concurrent chemoradiotherapy at the dose of 50.4 Gy with elective nodal irradiation for Stage II-III esophageal carcinoma.
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Che | 2013 |
Phase II study of concurrent chemoradiotherapy at the dose of 50.4 Gy with elective nodal irradiation for Stage II-III esophageal carcinoma.
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Che | 2013 |
Phase II study of concurrent chemoradiotherapy at the dose of 50.4 Gy with elective nodal irradiation for Stage II-III esophageal carcinoma.
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Che | 2013 |
Phase II study of concurrent chemoradiotherapy at the dose of 50.4 Gy with elective nodal irradiation for Stage II-III esophageal carcinoma.
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Che | 2013 |
Definitive chemoradiation therapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) in advanced esophageal cancer: a phase 2 trial (KDOG 0501-P2).
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradioth | 2014 |
A Phase 1/2 Study of Definitive Chemoradiation Therapy Using Docetaxel, Nedaplatin, and 5-Fluorouracil (DNF-R) for Esophageal Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Disease-Free Survival; Doce | 2015 |
[Phase II clinical trial of concurrent chemoradiotherapy (cisplatin plus 5-fluorouracil) for esophageal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2008 |
Prospective non-randomized study of preoperative concurrent platinum plus 5-fluorouracil-based chemoradiotherapy with or without paclitaxel in esophageal cancer patients: long-term follow-up.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogen | 2010 |
[Efficacy of late accelerated hyperfractionated conformal radiotherapy combined with capecitabine for esophageal carcinoma].
Topics: Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Squamous Cell; Chemoradiotherapy; Deoxycyt | 2011 |
Phase I evaluation of TNFerade biologic plus chemoradiotherapy before esophagectomy for locally advanced resectable esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2012 |
Phase II study of cisplatin and 5-fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG)/Japan Clinical Oncology Group trial (JCOG9516).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2004 |
Phase II study of cisplatin and 5-fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG)/Japan Clinical Oncology Group trial (JCOG9516).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2004 |
Phase II study of cisplatin and 5-fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG)/Japan Clinical Oncology Group trial (JCOG9516).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2004 |
Phase II study of cisplatin and 5-fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG)/Japan Clinical Oncology Group trial (JCOG9516).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2004 |
A phase I/II study of nedaplatin and 5-fluorouracil with concurrent radiotherapy in patients with esophageal cancer.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Esop | 2006 |
A phase I/II study of nedaplatin and 5-fluorouracil with concurrent radiotherapy in patients with esophageal cancer.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Esop | 2006 |
A phase I/II study of nedaplatin and 5-fluorouracil with concurrent radiotherapy in patients with esophageal cancer.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Esop | 2006 |
A phase I/II study of nedaplatin and 5-fluorouracil with concurrent radiotherapy in patients with esophageal cancer.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Esop | 2006 |
Concurrent chemotherapy and radiation therapy for locally advanced carcinoma of the esophagus.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Esophage | 1995 |
Induction therapy for esophageal cancer with paclitaxel and hyperfractionated radiotherapy: a phase I and II study.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 1997 |
Concomitant 5-fluorouracil infusion and high-dose radiation for stage III non-small cell lung cancer.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Combined Modality Therapy; Esophagit | 1989 |
12 other studies available for fluorouracil and Esophagitis
| Article | Year |
|---|---|
Cetuximab-induced esophageal ulcer: the first report in literature.
Topics: Abdomen, Acute; Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2014 |
A rare cause of esophagitis with crystal deposition.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Crystallization; Esoph | 2015 |
Clinical Study on Lobaplatin Combined with 5-Fu and Concurrent Radiotherapy in Treating Patients with Inoperable Esophageal Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Carcinoma, Squamous Cell | 2015 |
[Efficacy of docetaxel and nedaplatin combined with concurrent intensity modulated radiation therapy in the treatment of esophageal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2012 |
[Hypersensitivity to radiation therapy in a patient with tuberous sclerosis: biological considerations about a clinical case].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2013 |
Primary chemoradiation as definitive treatment for unresectable cancer of the trachea.
Topics: Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy | 2003 |
The potentiation of radiation effects with 5-fluoro-uracil.
Topics: Aged; Carcinoma, Squamous Cell; Esophagitis; Fluorouracil; Humans; Lung; Lung Neoplasms; Male; Middl | 1960 |
FLUORINATED PYRIMIDINE THERAPY OF ADVANCED GASTROINTESTINAL CANCER.
Topics: Alopecia; Colonic Neoplasms; Drug Eruptions; Esophagitis; Fluorouracil; Gallbladder Neoplasms; Human | 1964 |
[The radiochemotherapy of the oesophageal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Degl | 2004 |
[Phase I study of CM-Na combined with concurrent radiochemotherapy for advanced esophageal carcinoma].
Topics: Adult; Aged; Alanine Transaminase; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamo | 2005 |
The safety and usefulness of high-dose-rate endoluminal brachytherapy as a boost in the treatment of patients with esophageal cancer with external beam radiation with or without chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brac | 2005 |
Fast neutron irradiation for locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Colitis; Cost-Benefit Analysis; Energy Transfer; Esophagitis; Evaluation Studies as | 1981 |